📊 INKT Key Takeaways
Is MiNK Therapeutics, Inc. (INKT) a Good Investment?
MiNK Therapeutics exhibits severe fundamental distress with negative shareholders' equity (-$12.7M), microscopic revenue ($80.8K), and massive operating losses ($2.9M) indicating technical insolvency and unsustainable cash burn. The company lacks a demonstrated revenue engine, burning $1.8M annually in free cash flow with an unclear path to profitability.
MiNK Therapeutics shows extremely weak fundamentals: revenue is negligible and declining sharply, while operating and net losses remain very large relative to its scale. The balance sheet is stressed by negative stockholders' equity and only modest liquidity coverage, and continued negative free cash flow raises concern about funding durability absent a meaningful improvement in commercialization or external capital support.
MiNK Therapeutics, Inc. Key Strengths (INKT)
- Maintains positive cash position of $9.5M providing approximately 5 years of runway at current burn rate
- Low debt burden simplifies capital structure and reduces seniority risk
- Current ratio of 1.38x indicates short-term liquidity is not immediately critical
- Cash and equivalents of $14.28M provide some near-term operating flexibility
- Diluted EPS improved year over year, indicating lower per-share loss pressure
- Low capital expenditure suggests an asset-light operating model
INKT Stock Risks: MiNK Therapeutics, Inc. Investment Risks
- Negative shareholders' equity of -$12.7M indicates technical balance sheet insolvency
- Severe operating cash burn of -$1.7M against negligible revenue of $80.8K demonstrates unsustainable unit economics
- Catastrophic profitability margins (Operating: -3565%, Net: -3392%) with no clear inflection point visible
- Heavy dependence on capital raises creating significant dilution risk to existing shareholders
- Minimal revenue growth (+4.4% YoY) insufficient to cover operational costs at any foreseeable scale
- Revenue fell 62.7% year over year and remains far too small to support operations
- Negative stockholders' equity of $-13.51M signals severe balance-sheet weakness
- Ongoing operating and free cash flow burn create material financing and going-concern risk
Key Metrics to Watch
- Revenue growth rate and achievement of material clinical/commercial milestones
- Monthly operating cash burn trend and updated runway estimates
- Successful capital raises and resulting shareholder dilution levels
- Path to positive operating cash flow and gross margin expansion
- Operating expense reduction initiatives relative to revenue generation capacity
- Quarterly cash burn relative to cash balance
- Revenue traction and operating loss trend
MiNK Therapeutics, Inc. (INKT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
MiNK Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
INKT Profit Margin, ROE & Profitability Analysis
INKT vs Healthcare Sector: How MiNK Therapeutics, Inc. Compares
How MiNK Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MiNK Therapeutics, Inc. Stock Overvalued? INKT Valuation Analysis 2026
Based on fundamental analysis, MiNK Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MiNK Therapeutics, Inc. Balance Sheet: INKT Debt, Cash & Liquidity
INKT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MiNK Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.86 indicates the company is currently unprofitable.
INKT Revenue Growth, EPS Growth & YoY Performance
MiNK Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
INKT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MiNK Therapeutics, Inc. (CIK: 0001840229)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INKT
What is the AI rating for INKT?
MiNK Therapeutics, Inc. (INKT) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INKT's key strengths?
Claude: Maintains positive cash position of $9.5M providing approximately 5 years of runway at current burn rate. Low debt burden simplifies capital structure and reduces seniority risk. ChatGPT: Cash and equivalents of $14.28M provide some near-term operating flexibility. Diluted EPS improved year over year, indicating lower per-share loss pressure.
What are the risks of investing in INKT?
Claude: Negative shareholders' equity of -$12.7M indicates technical balance sheet insolvency. Severe operating cash burn of -$1.7M against negligible revenue of $80.8K demonstrates unsustainable unit economics. ChatGPT: Revenue fell 62.7% year over year and remains far too small to support operations. Negative stockholders' equity of $-13.51M signals severe balance-sheet weakness.
What is INKT's revenue and growth?
MiNK Therapeutics, Inc. reported revenue of $80.8K.
Does INKT pay dividends?
MiNK Therapeutics, Inc. does not currently pay dividends.
Where can I find INKT SEC filings?
Official SEC filings for MiNK Therapeutics, Inc. (CIK: 0001840229) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INKT's EPS?
MiNK Therapeutics, Inc. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is INKT's fundamental grade?
Based on our AI fundamental analysis in June 2026, MiNK Therapeutics, Inc. has a D grade with 88% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is INKT stock overvalued or undervalued?
Valuation metrics for INKT: ROE of N/A (sector avg: 15%), net margin of -3,392.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is INKT's AI grade for 2026?
Our dual AI analysis gives MiNK Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INKT's free cash flow?
MiNK Therapeutics, Inc.'s operating cash flow is $-1.7M, with capital expenditures of $73.6K. FCF margin is -2,234.4%.
How does INKT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,392.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.38 (avg: 2).